MA49760A - Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique - Google Patents

Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique

Info

Publication number
MA49760A
MA49760A MA049760A MA49760A MA49760A MA 49760 A MA49760 A MA 49760A MA 049760 A MA049760 A MA 049760A MA 49760 A MA49760 A MA 49760A MA 49760 A MA49760 A MA 49760A
Authority
MA
Morocco
Prior art keywords
mavacamten
treatment
hypertrophic cardiomyopathy
hypertrophic
cardiomyopathy
Prior art date
Application number
MA049760A
Other languages
English (en)
French (fr)
Inventor
Marc Evanchik
Eric Green
Joseph Lambing
June H Lee
Marc J Semigran
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of MA49760A publication Critical patent/MA49760A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
MA049760A 2017-08-04 2018-08-03 Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique MA49760A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US201862671585P 2018-05-15 2018-05-15

Publications (1)

Publication Number Publication Date
MA49760A true MA49760A (fr) 2020-06-10

Family

ID=63350605

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049760A MA49760A (fr) 2017-08-04 2018-08-03 Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique

Country Status (17)

Country Link
US (5) US20200054636A1 (enExample)
EP (2) EP3661514B1 (enExample)
JP (3) JP2020529996A (enExample)
KR (2) KR20250116181A (enExample)
CN (2) CN111182901A (enExample)
AU (2) AU2018311974B2 (enExample)
CA (1) CA3071948A1 (enExample)
IL (2) IL322175A (enExample)
LT (1) LT3661514T (enExample)
MA (1) MA49760A (enExample)
MX (3) MX2020001406A (enExample)
MY (1) MY208231A (enExample)
RU (1) RU2020109345A (enExample)
SG (2) SG10202112960QA (enExample)
SM (1) SMT202500413T1 (enExample)
UY (1) UY37834A (enExample)
WO (1) WO2019028360A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI835770B (zh) 2018-01-19 2024-03-21 美商胞質動力學公司 心肌節抑制劑
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
TW202134259A (zh) * 2019-11-10 2021-09-16 美商邁奧卡迪亞公司 用肌凝蛋白調節劑之治療方法
CA3165995A1 (en) * 2020-01-28 2021-08-05 Lorena KORDIC Solid state forms of mavacamten and process for preparation thereof
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
TW202227420A (zh) 2020-11-20 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 三嗪二酮類衍生物、其製備方法及其在醫藥上的應用
US20240082248A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
EP4301760A1 (en) 2021-03-04 2024-01-10 Cytokinetics, Inc. Cardiac sarcomere inhibitors
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
PL4370116T3 (pl) * 2021-07-16 2025-04-28 Cytokinetics, Inc. Schematy dawkowania afikamtenu do leczenia obturacyjnej kardiomiopatii przerostowej
EP4404846B1 (en) * 2021-09-24 2025-10-08 Koninklijke Philips N.V. Methods and systems for generating likelihood of heart failure with preserved ejection fraction (hfpef)
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache

Also Published As

Publication number Publication date
CN111182901A (zh) 2020-05-19
SG10202112960QA (en) 2021-12-30
US20240423981A1 (en) 2024-12-26
IL272300B1 (en) 2025-08-01
TW201916882A (zh) 2019-05-01
MX2024000348A (es) 2024-01-26
LT3661514T (lt) 2025-11-10
AU2018311974B2 (en) 2024-03-07
SMT202500413T1 (it) 2025-11-10
US20220226324A1 (en) 2022-07-21
IL322175A (en) 2025-09-01
JP2020529996A (ja) 2020-10-15
US20220313695A1 (en) 2022-10-06
AU2024203872A1 (en) 2024-06-27
JP2025020292A (ja) 2025-02-12
SG11202000549TA (en) 2020-02-27
KR20250116181A (ko) 2025-07-31
EP3661514A1 (en) 2020-06-10
AU2018311974A1 (en) 2020-02-06
IL272300A (en) 2020-03-31
CN118593507A (zh) 2024-09-06
MX2024008096A (es) 2024-07-15
CA3071948A1 (en) 2019-02-07
US20250213565A1 (en) 2025-07-03
WO2019028360A1 (en) 2019-02-07
EP4659806A2 (en) 2025-12-10
MX2020001406A (es) 2020-03-09
JP2023065372A (ja) 2023-05-12
UY37834A (es) 2019-02-28
MY208231A (en) 2025-04-25
EP3661514B1 (en) 2025-09-17
KR20200035973A (ko) 2020-04-06
US20200054636A1 (en) 2020-02-20
RU2020109345A (ru) 2021-09-06

Similar Documents

Publication Publication Date Title
MA49760A (fr) Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique
EP3455205A4 (en) Peptidomimetics for the treatment of norovirus infection
MA47719A (fr) Esketamine pour le traitement de la dépression
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
MA44119A (fr) Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinale
EP3572050A4 (en) EXCREMENTAL TREATMENT FOR USE IN COLOSTOMIES
MA44676A (fr) Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius
MA54290A (fr) Inhibiteur de kinase aurora a destiné à être utilisé dans le traitement du neuroblastome
EP3509594C0 (en) A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis
EP3813870C0 (en) CCR5 INHIBITOR FOR USE IN THE TREATMENT OF CANCER
ME03351B (me) Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije
EP3331526A4 (en) NICOTIN-DEGREEING ENZYMES FOR THE TREATMENT OF NICOTINE DEPENDENCE AND NICOTINE POISONING
EP3705545A4 (en) Surface treatment composition
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
EP3893874A4 (en) Crenolanib combination therapy
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
EP4008696A4 (en) SURFACE TREATMENT AGENT
EP4001364A4 (en) Surface treatment agent
EP3442538A4 (en) TREATMENT OF EXTRAPYRAMIDAL SYNDROME WITH TRAPIDILE
EP3419981A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
MA43861A (fr) Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie
MA54512A (fr) Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer
EP3873528A4 (en) Rasopathy treatment
MA55507A (fr) Macitentan destiné à être utilisé dans le traitement de l'hypertension portopulmonaire
EP3406258A4 (en) MEDICINAL PRODUCT FOR USE IN THE TREATMENT OF GICHT